Precigen Inc (PGEN)

Over the past six months, Precigen's stock has been impacted by the FDA approval of PAPZIMEOS, robust uptake and revenue expectations, and the J-code assignment for PAPZIMEOS. Full year 2025 financial results and analyst bullishness also contributed positively. An announcement regarding Q1 2026 earnings led to selling pressure, while presentations and conferences helped reinforce the company's positioning. High insider ownership and positive insider trading signals have also buoyed the stock.

The provided search results do not contain specific information regarding demand seasonality for Precigen, Inc.'s products and services. Demand is likely driven more by disease prevalence, regulatory approvals, market access, and clinical trial outcomes rather than traditional seasonal patterns.

Precigen, Inc. is a biotechnology and biopharmaceutical company focused on precision medicines, operating in the healthcare sector. They develop gene and cell therapies and immunotherapies for immuno-oncology, autoimmune disorders, and infectious diseases. Their products include PAPZIMEOS, an FDA-approved therapy for recurrent respiratory papillomatosis (RRP); the AdenoVerse™ Platform for gene delivery; the UltraCAR-T™ Platform for CAR-T therapies; and investigational programs like PRGN-2009, PRGN-3006, PRGN-3005, and PRGN-3007. They also have the UltraPorator® device for rapid manufacturing.

Precigen, Inc. is headquartered in Germantown, Maryland, United States, where its manufacturing facility is also located. The company operates in the United States and has filed a Marketing Authorization Application for PAPZIMEOS with the European Medicines Agency (EMA), indicating ambitions for global expansion.

Precigen's brand reputation in the past year appears to be positive, largely driven by the FDA approval for PAPZIMEOS. The company is now seen as a commercial-stage biopharmaceutical entity with an innovative precision medicine. An expert consensus paper recommended PAPZIMEOS as the new standard of care first-line treatment for adults with RRP, further enhancing the company's reputation.

Precigen, Inc. has a mixed ownership structure with significant institutional and insider holdings. Key institutional shareholders include Patient Capital Management, LLC, BlackRock, Inc., and others. Randal J. Kirk is the largest individual shareholder, owning 73.05% of the company's shares. Approximately 38.55% of the company's stock is owned by institutional shareholders and 82.76% by Precigen insiders.